Novo Ventures, an investor in the biological research tool producer since its series A round, returned for a series D that took its total funding to $86m.
US-based biopharmaceutical tool producer Unchained Labs has secured $17m in a series D round backed by Novo Ventures, a strategic investment vehicle for pharmaceutical firm Novo.
Venture capital firm Canaan Partners, VC fund Tri-Valley Ventures and TPG Biotech, a branch of private equity group TPG, also participated in the round, which boosted the company’s overall funding to $86m according to a fact sheet on its website.
Unchained Labs provides equipment for the biological research industry, including a formulation preparation system,…
